Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.
[waldenström macroglobulinemia]
Waldenström
's
macroglobulinemia
(
WM
)
is
a
B-
cell
proliferative
malignancy
characterized
by
immunoglobulin
M
monoclonal
gammopathy
and
bone
marrow
infiltration
by
lymphoplasmacytic
cells
.
Clinical
features
and
cytogenetics
of
WM
in
Asia
including
Republic
of
Korea
remain
unclear
.
Moreover
,
no
study
has
reported
treatment
outcomes
in
patients
with
WM
treated
with
novel
agent
combined
with
conventional
chemotherapy
.
This
study
investigated
clinical
features
and
assessed
treatment
outcomes
with
novel
agent
and
conventional
chemotherapy
in
Republic
of
Korea
.
Data
from
all
(
n
=
71
)
patients
with
newly
diagnosed
WM
at
17
hospitals
who
received
chemotherapy
between
January
2005
and
December
2012
were
collected
retrospectively
.
The
median
age
of
patients
was
66
years
(
range
:
37
-
92
years
)
and
male
to
female
ratio
was
5
:
1
.
Patients
treated
with
novel
agent
combined
chemotherapy
displayed
higher
overall
response
rate
(
ORR
)
compared
to
conventional
chemotherapy
alone
(
92
.
9
%
versus
52
.
6
%
,
P
=
0
.
006
)
.
The
5
-
year
overall
survival
rate
was
62
.
6
%
(
95
%
confidence
interval
:
34
.
73
-
111
.
07
)
.
Use
of
novel
agents
produced
higher
ORR
but
survival
benefit
was
not
apparent
due
to
the
small
number
of
patients
and
short
follow-up
duration
.
Further
studies
are
needed
to
confirm
the
efficacy
of
novel
agents
in
patients
with
WM
.
